High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes

Journal of Clinical Psychopharmacology

Volumn 28, Issue 2, 2008, Pages 240-241

  Mech, Arnold W ^a  

^a Mech Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; CLONAZEPAM; ESCITALOPRAM; LITHIUM; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE; ZONISAMIDE;

ADULT; ANAMNESIS; BIPOLAR I DISORDER; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVENING DOSAGE; FEMALE; HUMAN; INSULIN RESISTANCE; LETTER; MALE; MIXED MANIA AND DEPRESSION; MONOTHERAPY; MORNING DOSAGE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SEDATION; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; BIPOLAR DISORDER; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN UPTAKE INHIBITORS; THIAZOLES; TREATMENT OUTCOME;

EID: 40949160238     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31816745de     Document Type: Letter

References (11)

1. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360.
2. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20(4):536-546.
3. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, doubleblind, placebo-controlled study. Br J Psychiatry. 2005;187:229-234.
4. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160(4):741-748.
5. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25(4):301-310.
6. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
7. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
8. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6-12.
9. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
10. Levy WO, Robichaux-Keene NR, Nunez C. No significant QTc interval changes with high-dose ziprasidone: a case series. J Psychiatr Pract. 2004;10(4):227-232.
11. Deutschman DA, Deutschman DH. High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: a case series. J Clin Psychopharmacol. 2007;27(5):513-514.